Yufei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yufei Wang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Aedin C. Culhane
University of Limerick, Limerick, Ireland
3 shared publications - Laurent Gatto
UCLouvain
2 shared publications - Michael Patrick Lynch
Limerick Digital Cancer Research Centre, Health Research Institute, School of Medicine, University of Limerick
2 shared publications - Wayne Anthony Marasco
Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
2 shared publications - Aitziber Buqué
Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA
1 shared publication - Alicia Buck
Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
demuxSNP: supervised demultiplexing scRNAseq using cell hashing and SNPs
Background Multiplexing single-cell RNA sequencing experiments reduces sequencing cost and facilitates larger scale studies. However, factors such as cell hashing quality and class size imbalance impact demultiplexing algorithm performance, reducing cost effectiveness Findings We propose a supervised algorithm, demuxSNP, leveraging both cell hashing and genetic variation between individuals (SNPs). The supervised algorithm addresses fundamental limitations in demultiplexing with only one data modality. The genetic variants (SNPs) of the subset of cells assigned with high confidence using a probabilistic hashing algorithm are used to train a KNN classifier that predicts the demultiplexing classes of unassigned or uncertain cells. We benchmark demuxSNP against hashing (HTODemux, cellhashR, GMM-demux, demuxmix) and genotype-free SNP (souporcell) methods on simulated and real data from renal cell cancer. Our results demonstrate that demuxSNP outperformed standalone hashing methods on low quality hashing data, improving overall classification accuracy and allowing more high RNA quality cells to be recovered. Through varying simulated doublet rates, we show genotype-free SNP methods are unable to identify biological samples with low cell counts at high doublet rates. When compared to unsupervised SNP demultiplexing methods, demuxSNP’s supervised approach was more robust to doublet rate in experiments with class size imbalance. Conclusions demuxSNP is a performant demultiplexing approach that uses hashing and SNP data to demultiplex datasets with low hashing quality where biological samples are genetically distinct. Unassigned cells (negatives) with high RNA quality can be recovered, making more cells available for analysis, especially when applied to data with low hashing quality or suspected misassigned cells. Pipelines for simulated data and processed benchmarking data for 5-50% doublets are publicly available. demuxSNP is available as an R/Bioconductor package (https://doi.org/doi:10.18129/B9.bioc.demuxSNP).
Open AccessdemuxSNP: supervised demultiplexing scRNAseq using cell hashing and SNPs
Background Multiplexing single-cell RNA sequencing experiments reduces sequencing cost and facilitates larger scale studies. However, factors such as cell hashing quality and class size imbalance impact demultiplexing algorithm performance, reducing cost effectiveness Findings We propose a supervised algorithm, demuxSNP, leveraging both cell hashing and genetic variation between individuals (SNPs). The supervised algorithm addresses fundamental limitations in demultiplexing with only one data modality. The genetic variants (SNPs) of the subset of cells assigned with high confidence using a probabilistic hashing algorithm are used to train a KNN classifier that predicts the demultiplexing classes of unassigned or uncertain cells. We benchmark demuxSNP against hashing (HTODemux, cellhashR, GMM-demux, demuxmix) and genotype-free SNP (souporcell) methods on simulated and real data from renal cell cancer. Our results demonstrate that demuxSNP outperformed standalone hashing methods on low quality hashing data, improving overall classification accuracy and allowing more high RNA quality cells to be recovered. Through varying simulated doublet rates, we show genotype-free SNP methods are unable to identify biological samples with low cell counts at high doublet rates. When compared to unsupervised SNP demultiplexing methods, demuxSNP’s supervised approach was more robust to doublet rate in experiments with class size imbalance. Conclusions demuxSNP is a performant demultiplexing approach that uses hashing and SNP data to demultiplex datasets with low hashing quality where biological samples are genetically distinct. Unassigned cells (negatives) with high RNA quality can be recovered, making more cells available for analysis, especially when applied to data with low hashing quality or suspected misassigned cells. Pipelines for simulated data and processed benchmarking data for 5-50% doublets are publicly available. demuxSNP is available as an R/Bioconductor package (https://doi.org/doi:10.18129/B9.bioc.demuxSNP).
- Open Access
- 2 January 2024
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 13
demuxSNP: supervised demultiplexing single-cell RNA sequencing using cell hashing and SNPs
Background: Multiplexing single-cell RNA sequencing experiments reduces sequencing cost and facilitates larger-scale studies. However, factors such as cell hashing quality and class size imbalance impact demultiplexing algorithm performance, reducing cost-effectiveness. Findings: We propose a supervised algorithm, demuxSNP, which leverages both cell hashing and genetic variation between individuals (single-nucletotide polymorphisms [SNPs]). demuxSNP addresses fundamental limitations in demultiplexing methods that use only one data modality. Some cells may be confidently demultiplexed using probabilistic hashing methods. demuxSNP uses these data to infer the genotype of singlet and doublet clusters and predict on cells assigned as negative, uncertain, or doublet using a nearest-neighbor approach adapted for missing data. We benchmarked demuxSNP against hashing, genotype-free SNP and hybrid methods on simulated and real data from renal cell cancer. demuxSNP outperformed standalone hashing methods on low-quality hashing data benchmark, improved overall classification accuracy, and allowed more high RNA quality cells to be recovered. Through varying simulated doublet rates, we showed that genotype-free SNP and hybrid methods that leverage them were impacted by class size imbalance and doublet rate. demuxSNP’s supervised approach was more robust to doublet rate in experiments with class size imbalance. Conclusions: demuxSNP uses hashing and SNP data to demultiplex datasets with low hashing quality where biological samples are genetically distinct. Unassigned or negative cells with high RNA quality are recovered, making more cells available for analysis. Data simulation and benchmarking pipelines as well as processed benchmarking data for 5–50% doublets are publicly available. demuxSNP is available as an R/Bioconductor package (https://doi.org/doi:10.18129/B9.bioc.demuxSNP).
- 2 January 2024
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 13
Open AccessdemuxSNP: supervised demultiplexing single-cell RNA sequencing using cell hashing and SNPs
Background: Multiplexing single-cell RNA sequencing experiments reduces sequencing cost and facilitates larger-scale studies. However, factors such as cell hashing quality and class size imbalance impact demultiplexing algorithm performance, reducing cost-effectiveness. Findings: We propose a supervised algorithm, demuxSNP, which leverages both cell hashing and genetic variation between individuals (single-nucletotide polymorphisms [SNPs]). demuxSNP addresses fundamental limitations in demultiplexing methods that use only one data modality. Some cells may be confidently demultiplexed using probabilistic hashing methods. demuxSNP uses these data to infer the genotype of singlet and doublet clusters and predict on cells assigned as negative, uncertain, or doublet using a nearest-neighbor approach adapted for missing data. We benchmarked demuxSNP against hashing, genotype-free SNP and hybrid methods on simulated and real data from renal cell cancer. demuxSNP outperformed standalone hashing methods on low-quality hashing data benchmark, improved overall classification accuracy, and allowed more high RNA quality cells to be recovered. Through varying simulated doublet rates, we showed that genotype-free SNP and hybrid methods that leverage them were impacted by class size imbalance and doublet rate. demuxSNP’s supervised approach was more robust to doublet rate in experiments with class size imbalance. Conclusions: demuxSNP uses hashing and SNP data to demultiplex datasets with low hashing quality where biological samples are genetically distinct. Unassigned or negative cells with high RNA quality are recovered, making more cells available for analysis. Data simulation and benchmarking pipelines as well as processed benchmarking data for 5–50% doublets are publicly available. demuxSNP is available as an R/Bioconductor package (https://doi.org/doi:10.18129/B9.bioc.demuxSNP).
- Open Access
- 31 October 2023
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 11 (12) , 1571-1577
Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium
The Arthur and Sandra Irving Cancer Immunology Symposium has been created as a platform for established cancer immunologists to mentor trainees and young investigators as they launch their research career in the field. By sharing their different paths to success, the senior faculty mentors provide an invaluable resource to support the development of the next generation of leaders in the cancer immunology community. This Commentary describes some of the key topics that were discussed during the 2022 symposium: scientific and career trajectory, leadership, mentoring, collaborations, and publishing. For each of these topics, established investigators discussed the elements that facilitate success in these areas as well as mistakes that can hinder progress. Herein, we outline the critical points raised in these discussions for establishing a successful independent research career. These points are highly relevant for the broader scientific community.
- 31 October 2023
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 11 (12) , 1571-1577
Open AccessLessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium
The Arthur and Sandra Irving Cancer Immunology Symposium has been created as a platform for established cancer immunologists to mentor trainees and young investigators as they launch their research career in the field. By sharing their different paths to success, the senior faculty mentors provide an invaluable resource to support the development of the next generation of leaders in the cancer immunology community. This Commentary describes some of the key topics that were discussed during the 2022 symposium: scientific and career trajectory, leadership, mentoring, collaborations, and publishing. For each of these topics, established investigators discussed the elements that facilitate success in these areas as well as mistakes that can hinder progress. Herein, we outline the critical points raised in these discussions for establishing a successful independent research career. These points are highly relevant for the broader scientific community.
- Open Access
- 6 May 2022
- Published by Elsevier in EBioMedicine
- Vol. 80, 104025
Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants
- 6 May 2022
- Published by Elsevier in EBioMedicine
- Vol. 80, 104025
Open AccessAnalysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants
- Open Access
- 31 December 2021
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 24, 385-399
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model
- 31 December 2021
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 24, 385-399
Open AccessAnti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model